MedPath

Inmagene LLC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

8

Active:1
Completed:3

Trial Phases

2 Phases

Phase 1:6
Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials

Phase 1
6 (75.0%)
Phase 2
2 (25.0%)

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Phase 2
Recruiting
Conditions
Atopic Dermatitis
Atopic Dermatitis Eczema
Eczema
Interventions
Drug: Placebo
First Posted Date
2025-06-26
Last Posted Date
2025-08-03
Lead Sponsor
Inmagene LLC
Target Recruit Count
220
Registration Number
NCT07037901
Locations
🇺🇸

Forest Hills Dermatology Group, Kew Gardens, New York, United States

🇺🇸

Apex Clinical Research Center, Mayfield Heights, Ohio, United States

🇺🇸

Dermatology of Seattle & Bellevue, Burien, Washington, United States

and more 4 locations

Safety and Pharmacokinetics of Subcutaneous Dose of IMG-007 in Healthy Participants

Phase 1
Terminated
Conditions
Healthy Volunteers
Interventions
Drug: Placebo
First Posted Date
2024-03-12
Last Posted Date
2024-12-12
Lead Sponsor
Inmagene LLC
Target Recruit Count
24
Registration Number
NCT06304740
Locations
🇦🇺

Linear Clinical Research, Perth, Australia

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants

Phase 1
Completed
Conditions
Alopecia Areata (AA)
Interventions
First Posted Date
2023-09-29
Last Posted Date
2025-04-30
Lead Sponsor
Inmagene LLC
Target Recruit Count
29
Registration Number
NCT06060977
Locations
🇺🇸

Northwest Arkansas Clinical Trials Center, PLLC/ Hull Dermatology P.A., Rogers, Arkansas, United States

🇺🇸

Torrance Clinical Research Institute Inc., Lomita, California, United States

🇺🇸

Alliance Clinical Research of Tampa, Tampa, Florida, United States

and more 14 locations

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)

Phase 1
Terminated
Conditions
Moderate-to-severe Atopic Dermatitis
Atopic Dermatitis
AD
Interventions
Drug: Placebo
First Posted Date
2023-08-09
Last Posted Date
2024-12-24
Lead Sponsor
Inmagene LLC
Target Recruit Count
13
Registration Number
NCT05984784
Locations
🇺🇸

Amicis Research Center, Valencia, California, United States

🇺🇸

Medical Research Center of Miami II Inc, Miami, Florida, United States

🇺🇸

Optimal Research Sites, Orange City, Florida, United States

and more 8 locations

Evaluate IMG-007 in Healthy Participants

Phase 1
Completed
Conditions
Healthy Participants
Interventions
Drug: IMG-007 or placebo
First Posted Date
2022-04-29
Last Posted Date
2023-06-28
Lead Sponsor
Inmagene LLC
Target Recruit Count
44
Registration Number
NCT05353972
Locations
🇦🇺

Linear Clinical Research, Nedlands, Western Australia, Australia

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.